Breast cancer is the most diagnosed cancer among women, with ~15% of breast cancer patients possessing a triple-negative breast cancer (TNBC) subtype, i.e., absence of estrogen and progesterone receptors (ER−, PR−), and lack of HER2 overexpression (HER2−) [1,2]. Here, ERBB2 is linked to triple-negative breast carcinoma.